LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Jun 6, 2022
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The LobularCard Trial is looking to find new genetic changes, called germline mutations, in women with lobular breast cancer. This type of cancer can be invasive or in situ, which means it hasn't spread yet. The study will use a special test that examines 113 different genes to see how often these mutations occur in patients. If a new harmful mutation is found, patients may receive personalized care, which could include regular screening or even preventive surgery, depending on the risk level.
To participate in this trial, women aged 65 to 74 who have been diagnosed with lobular breast cancer and have a blood sample stored in a biobank can apply. Patients will be monitored closely, with follow-up visits every six months for the first five years and once a year after that. This trial is currently recruiting participants, and it aims to improve understanding and treatment options for lobular breast cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion criteria:
- • 1. All LBC observed retrospectively at the European Institute of Oncology, with a proved diagnosis of LBC (biopsy or operated)
- • 2. Patients with blood available in biobank Exclusion criteria
- • Patients with a previous cancer (except skin basal cell carcinoma)
- • Patients with ductal or mixed BC
About European Institute Of Oncology
The European Institute of Oncology (IEO) is a leading research and treatment center based in Milan, Italy, dedicated to advancing cancer care through innovative clinical research and personalized medicine. Renowned for its commitment to multidisciplinary approaches, IEO integrates cutting-edge research with clinical practice to improve patient outcomes. The institute actively sponsors and conducts clinical trials across various cancer types, fostering collaboration between oncologists, researchers, and industry partners. With a focus on translating scientific discoveries into effective therapies, IEO plays a pivotal role in the global fight against cancer, contributing to the development of new treatment protocols and enhancing the understanding of oncological diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Patients applied
Trial Officials
Giovanni Corso, PhD, MD
Principal Investigator
European Institute of Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials